SHAREHOLDERS' EQUITY:

3 Months Ended

Sep. 30, 2012

SHAREHOLDERS' EQUITY:

SHAREHOLDERS' EQUITY:

4. SHAREHOLDERS’ EQUITY:

Net Income Per Share:

The Company’s basic earnings per share is calculated as net income divided by weighted average common shares outstanding, excluding unvested outstanding RSAs and RSUs. The Company’s dilutive earnings per share is calculated as net income divided by weighted average common shares and common share equivalents outstanding, which includes shares issuable under the Company’s stock option plan and long-term incentive plan, and dilutive securities. Stock-based awards with exercise prices greater than the average market value of the Company’s common stock are excluded from the computation of diluted earnings per share. The Company’s dilutive earnings per share will also reflect the assumed conversion under the Company’s convertible debt if the impact is dilutive, along with the exclusion of interest expense, net of taxes. The impact of the convertible debt is excluded from the computation of diluted earnings per share when interest expense per common share obtainable upon conversion is greater than basic earnings per share.

The following table sets forth a reconciliation of shares used in the computation of basic and diluted earnings per share:

	For the Three Months Ended September 30,
	2012	2011
	(Shares in thousands)
Weighted average shares for basic earnings per share	57,283	56,849
Effect of dilutive securities:
Dilutive effect of stock-based compensation	67	249
Dilutive effect of convertible debt	11,239	—
Weighted average shares for diluted earnings per share	68,589	57,098

The following table sets forth the awards which are excluded from the various earnings per share calculations:

	For the Three Months Ended September 30,
	2012	2011
	(Shares in thousands)
Basic earnings per share:
RSAs (1)	501	858
RSUs (1)	173	215
	674	1,073
Diluted earnings per share:
Stock options (2)	585	826
SARs (2)	444	1,030
RSAs (2)	—	767
Shares issuable upon conversion of debt (3)	—	11,184
	1,029	13,807

(1) Awards were not vested

(2) Awards were anti-dilutive

(3) Shares were anti-dilutive for the three months ended September 30, 2011.

The following table sets forth a reconciliation of the net income from continuing operations available to common shareholders and the net income from continuing operations for diluted earnings per share under the if-converted method:

	For the Three Months Ended September 30,
	2012		2011
	(Dollars in thousands)
Net income from continuing operations available to common shareholders (as restated)	$	34,647	$	5,622
Effect of dilutive securities:
Interest on convertible debt, net of taxes	2,130		—
Net income from continuing operations for diluted earnings per share (as restated)	$	36,777	$	5,622

Additional Paid-In Capital:

The change in additional paid-in capital during the three months ended September 30, 2012 was due to the following:

	(Dollars in thousands)
Balance, June 30, 2012	$	346,943
Stock-based compensation	1,818
Vested stock option and stock appreciation right expirations	(1,126		)
Taxes related to restricted stock	(105		)
Net tax loss from stock-based compensation plans	(165		)
Proceeds from exercise of stock options and stock appreciation rights	45
Other	(2		)
Balance, September 30, 2012	$	347,408

Accumulated Other Comprehensive Income:

The Company completed the sale of its investment in Provalliance during the three months ended September 30, 2012 and subsequently liquidated all foreign entities with Euro denominated operations.  Amounts previously classified within accumulated other comprehensive income that were recognized in earnings were foreign currency translation rate gain adjustments of $43.4 million, as restated, a cumulative tax-effected net loss of $7.9 million associated with a cross-currency swap that was settled in fiscal year 2007 that hedged the Company’s European operations, and a $1.7 million net loss associated with cash repatriation from the Company’s European operations, which nets to $33.8 million, as restated.